Skip to content
OpenCapital
Get started

Alnylam Pharmaceuticals ALNY Business Segments

Income StatementBalance SheetCash FlowRatiosSegments
QuarterlyAnnualTTM
YoY
SimplifiedDetailed
FY'25FY'24FY'23FY'22
Total revenues by Product
AMVUTTRA$2.31B+138%$970.45M+74.0%$557.84M+495%$93.8M—
GIVLAARI$308.49M+20.6%$255.87M+16.7%$219.25M+26.6%$173.14M+35.5%
ONPATTRO$172.79M-31.7%$252.86M-28.7%$354.55M-36.4%$557.61M+17.5%
OXLUMO$191.44M+14.6%$167.05M+52.1%$109.84M+57.4%$69.78M+17.1%

Chart any of these lines over time, or line them up against competitors.

Compare these in charts →

Questions, answered.

How does Alnylam Pharmaceuticals break its business down?
Alnylam Pharmaceuticals (ALNY) reports total revenues by product across 4 parts — AMVUTTRA, GIVLAARI, ONPATTRO and OXLUMO. Each is extracted from the segment footnotes and tracked over time.
Where does Alnylam Pharmaceuticals's segment data come from?
Segment breakdowns are pulled from the segment footnotes in Alnylam Pharmaceuticals's SEC filings (the XBRL dimensional tags), so every line ties back to a reported figure. Switch between quarterly, annual, and TTM, or open any segment for its full history.